NCI-H2087 cell

NCI-H2087 is a human non-small cell lung carcinoma (NSCLC) cell line derived from the metastatic site (specifically, a lymph node) of an adult patient with lung adenocarcinoma. This cell line is epithelial in morphology and is commonly utilized in studies investigating lung cancer pathogenesis, therapeutic responses, and molecular profiling of metastatic adenocarcinomas. It exhibits characteristics consistent with its origin, including expression of epithelial markers and various genetic alterations typical of lung adenocarcinomas. Genetically, NCI-H2087 is known to harbor mutations relevant to oncogenesis and therapy resistance in NSCLC. Most notably, it contains a KRAS mutation, which is associated with constitutive activation of downstream signaling pathways such as MAPK and PI3K-AKT, leading to enhanced cell proliferation and survival. The presence of this mutation makes NCI-H2087 a valuable model for studying KRAS-driven tumorigenesis and for evaluating targeted inhibitors that disrupt KRAS signaling. Additionally, the cell line is p53 mutant, which can contribute to impaired apoptosis and genomic instability, further supporting its utility in preclinical cancer biology and drug screening research.

SKU:BHC11101696

• SDS (0191273EA8E271FABE06F57EB9E9AE9D)
• Product Sheet (0191273EA8E271FABE06F57EB9E9AE9D)
• NCI-H2087 305824-101025 Cytion CoA (PDF)

Mutational profile: Mutation: ATM, Simple, p.Glu848Gln (c.2542G>C), Heterozygous, BRAF, Simple, p.Leu597Val (c.1789C>G), Heterozygous, MYC, Simple, p.Glu54Lys (c.160G>A), Heterozygous, NRAS, Simple, p.Gln61Lys (c.181C>A), Heterozygous, TP53, Simple, p.Val157Phe (c.469G>T), Homozygous

• cultureMedium: RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)
• supplements: 51 hours
• dissociationReagent: Accutase
• seedingDensity: 4 x 104 cells/cm2
• freezeMedium: As a cryopreservation medium, use complete growth medium + 10% DMSO for adequate post-thaw viability.